Contract facts
UnrestrictedNo full NAICS 325413 intel page yet. Browse NAICS intelligence
Reagents to Include Chemistry/Immunology Analyzers is a federal Unrestricted award for W40m Rhco Pacific held by Ortho-Clinical Diagnostics Singapore Pte. Ltd.. Korea Branch. Estimated value $2.5M ($2M obligated). Current period of performance ends Sep 30, 2026 (potential Sep 30, 2027). Last award drew 1 bidder. Related solicitation W81K0223Q0004.
Reagents to include chemistry/immunology analyzers. Latest action is a modification.
Recompete timing
PublicCurrent PoP ended Sep 30, 2026 (17 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on W81K0223P0026? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordOrtho-Clinical Diagnostics Singapore Pte. Ltd.. Korea Branch — $2.4M obligated across 8 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract W81K0223P0026?
W81K0223P0026 (Reagents to include chemistry immunology) is a W40m Rhco Pacific award with a potential value of $2.5M, currently held by Ortho-Clinical Diagnostics Singapore Pte. Ltd.. Korea Branch. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is W81K02-23-P-0026?
W81K02-23-P-0026 is the dashed form of PIID W81K0223P0026 (Reagents to include chemistry immunology), held by Ortho-Clinical Diagnostics Singapore Pte. Ltd.. Korea Branch. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded W81K0223P0026?
W40m Rhco Pacific awarded W81K0223P0026 to Ortho-Clinical Diagnostics Singapore Pte. Ltd.. Korea Branch (potential $2.5M).
Who is the incumbent on W81K0223P0026?
Ortho-Clinical Diagnostics Singapore Pte. Ltd.. Korea Branch is the incumbent with $2.4M across 8 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.
When does Ortho-Clinical Diagnostics Singapore Pte. Ltd.. Korea Branch’s W81K0223P0026 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on W81K0223P0026? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.